Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Natera Inc (NTRA)

Natera Inc (NTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,957,500
  • Shares Outstanding, K 138,321
  • Annual Sales, $ 1,697 M
  • Annual Income, $ -190,430 K
  • EBIT $ -352 M
  • EBITDA $ -321 M
  • 60-Month Beta 1.64
  • Price/Sales 13.35
  • Price/Cash Flow N/A
  • Price/Book 23.71

Options Overview Details

View History
  • Implied Volatility 58.92% (+0.34%)
  • Historical Volatility 41.38%
  • IV Percentile 81%
  • IV Rank 48.73%
  • IV High 86.29% on 04/08/25
  • IV Low 32.92% on 06/16/25
  • Expected Move (DTE 24) 22.86 (10.92%)
  • Put/Call Vol Ratio 0.60
  • Today's Volume 285
  • Volume Avg (30-Day) 686
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 13,580
  • Open Int (30-Day) 13,675
  • Expected Range 186.49 to 232.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.46
  • Number of Estimates 5
  • High Estimate -0.28
  • Low Estimate -0.68
  • Prior Year -0.41
  • Growth Rate Est. (year over year) -12.20%

Price Performance

See More
Period Period Low Period High Performance
1-Month
194.02 +7.90%
on 02/06/26
246.26 -14.99%
on 01/26/26
-32.23 (-13.34%)
since 01/23/26
3-Month
194.02 +7.90%
on 02/06/26
256.36 -18.34%
on 01/07/26
-21.28 (-9.23%)
since 11/21/25
52-Week
125.38 +66.97%
on 04/07/25
256.36 -18.34%
on 01/07/26
+47.04 (+28.98%)
since 02/21/25

Most Recent Stories

More News
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

Interventional trial validates adaptive Signatera-guided treatment approach, achieving strong 63% response rate while reducing chemotherapy exposure in 74% of patients ...

NTRA : 209.35 (-1.31%)
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2025, after the market...

NTRA : 209.35 (-1.31%)
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Large prospective study to evaluate a non-invasive prenatal screening test

NTRA : 209.35 (-1.31%)
Natera Submits Signatera™ CDx PMA to FDA

Application backed by landmark phase 3 data validating MRD-guided treatment in bladder cancer

NTRA : 209.35 (-1.31%)
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

ACES-EMB is the first randomized-controlled trial to compare dd-cfDNA surveillance to routine biopsy in organ transplantation, highlighting the benefits of Prospera™ in organ rejection

NTRA : 209.35 (-1.31%)
Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

New publication shows that Prospera-guided care helped >75% of low-risk patients safely avoid routine transbronchial biopsies performed at 9 months

NTRA : 209.35 (-1.31%)
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds

2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds

NTRA : 209.35 (-1.31%)
SYK : 384.73 (+1.18%)
SUPN : 50.69 (-0.33%)
Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

Study reports high sensitivity and specificity, enabling MolDX submission and path to reimbursement in CRC

NTRA : 209.35 (-1.31%)
Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

EXPAND clinical trial to be presented; data support Fetal Focus™ sgNIPT for inherited conditions

NTRA : 209.35 (-1.31%)
Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

New AI-derived model integrates longitudinal ctDNA and clinical data with digital pathology and tumor sequencing data, to refine recurrence risk assessment and outcomes prediction

NTRA : 209.35 (-1.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.

See More

Key Turning Points

3rd Resistance Point 218.35
2nd Resistance Point 215.61
1st Resistance Point 212.48
Last Price 209.35
1st Support Level 206.62
2nd Support Level 203.88
3rd Support Level 200.75

See More

52-Week High 256.36
Last Price 209.35
Fibonacci 61.8% 206.33
Fibonacci 50% 190.87
Fibonacci 38.2% 175.41
52-Week Low 125.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar